Wall Street analysts expect Clearside Biomedical Inc (NASDAQ:CLSD) to post ($0.56) earnings per share for the current quarter, according to Zacks. Zero analysts have made estimates for Clearside Biomedical’s earnings. The highest EPS estimate is ($0.32) and the lowest is ($0.76). Clearside Biomedical posted earnings of ($0.65) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 13.8%. The firm is scheduled to issue its next earnings report on Wednesday, March 13th.

According to Zacks, analysts expect that Clearside Biomedical will report full year earnings of ($2.57) per share for the current fiscal year, with EPS estimates ranging from ($2.77) to ($2.33). For the next financial year, analysts expect that the firm will post earnings of ($1.31) per share, with EPS estimates ranging from ($1.50) to ($1.04). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research firms that cover Clearside Biomedical.

Clearside Biomedical (NASDAQ:CLSD) last announced its quarterly earnings data on Thursday, November 8th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.12).

CLSD has been the subject of a number of recent analyst reports. ValuEngine upgraded Clearside Biomedical from a “hold” rating to a “buy” rating in a research note on Tuesday, November 6th. Needham & Company LLC set a $4.00 price objective on Clearside Biomedical and gave the company a “buy” rating in a research note on Tuesday, November 6th. Laidlaw set a $5.00 price objective on Clearside Biomedical and gave the company a “buy” rating in a research note on Tuesday, November 6th. JPMorgan Chase & Co. downgraded Clearside Biomedical from an “overweight” rating to an “underweight” rating in a research note on Monday, November 5th. Finally, Janney Montgomery Scott set a $4.00 price objective on Clearside Biomedical and gave the company a “buy” rating in a research note on Tuesday, November 6th. Three research analysts have rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the company. Clearside Biomedical presently has an average rating of “Hold” and a consensus price target of $12.71.

NASDAQ:CLSD traded up $0.05 during trading on Thursday, reaching $1.41. The company’s stock had a trading volume of 177,400 shares, compared to its average volume of 532,895. The company has a market capitalization of $43.55 million, a PE ratio of -0.61 and a beta of -4.34. The company has a debt-to-equity ratio of 0.22, a current ratio of 4.59 and a quick ratio of 4.59. Clearside Biomedical has a 12 month low of $1.31 and a 12 month high of $15.33.

Several hedge funds have recently bought and sold shares of CLSD. Kornitzer Capital Management Inc. KS grew its stake in shares of Clearside Biomedical by 23.7% during the 2nd quarter. Kornitzer Capital Management Inc. KS now owns 92,800 shares of the company’s stock worth $992,000 after acquiring an additional 17,800 shares during the period. Alps Advisors Inc. bought a new position in shares of Clearside Biomedical during the 2nd quarter worth $496,000. Rhumbline Advisers grew its stake in shares of Clearside Biomedical by 43.2% during the 2nd quarter. Rhumbline Advisers now owns 26,703 shares of the company’s stock worth $285,000 after acquiring an additional 8,057 shares during the period. Schwab Charles Investment Management Inc. grew its stake in shares of Clearside Biomedical by 56.0% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 60,222 shares of the company’s stock worth $644,000 after acquiring an additional 21,622 shares during the period. Finally, GSA Capital Partners LLP bought a new position in shares of Clearside Biomedical during the 2nd quarter worth $534,000. Institutional investors own 57.94% of the company’s stock.

About Clearside Biomedical

Clearside Biomedical, Inc, a late-stage clinical biopharmaceutical company, develops pharmacological therapies to treat blinding diseases of the eye. It is developing suprachoroidal injection of CLS-TA, a proprietary preservative-free formulation of the corticosteroid triamcinolone acetonide, which is in Phase III clinical trial for the treatment of macular edema associated with non-infectious uveitis; suprachoroidal injection of CLS-TA and a concomitant intravitreal injection of Eylea, an inhibitor of vascular endothelial growth factor that is in Phase III clinical trial to treat macular edema associated with retinal vein occlusion; and suprachoroidal injection of CLS-TA alone or together with intravitreal injection of Eylea that is in phase II clinical trial for diabetic macular edema.

Featured Story: What is the Rule of 72?

Get a free copy of the Zacks research report on Clearside Biomedical (CLSD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Clearside Biomedical (NASDAQ:CLSD)

Receive News & Ratings for Clearside Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.